IDEAYA Biosciences (IDYA) Revenue & Revenue Breakdown
IDEAYA Biosciences Revenue Highlights
Latest Revenue (Y)
$7.00M
Latest Revenue (Q)
$7.00M
Main Segment (Y)
Methionine Adenosyl Transferase2 A Program Supply
IDEAYA Biosciences Revenue by Period
IDEAYA Biosciences Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $7.00M | -70.07% |
2023-12-31 | $23.39M | -54.08% |
2022-12-31 | $50.93M | 82.28% |
2021-12-31 | $27.94M | 43.01% |
2020-12-31 | $19.54M | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | - |
IDEAYA Biosciences generated $7.00M in revenue during NA 2024, up -70.07% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
IDEAYA Biosciences Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-12-31 | $7.00M | 100.00% |
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $3.92M | -51.19% |
2023-09-30 | $8.04M | 126.81% |
2023-06-30 | $3.54M | -55.03% |
2023-03-31 | $7.88M | 95.92% |
2022-12-31 | $4.02M | -86.46% |
2022-09-30 | $29.70M | 407.59% |
2022-06-30 | $5.85M | -48.49% |
2022-03-31 | $11.36M | 283.36% |
2021-12-31 | $2.96M | -66.99% |
2021-09-30 | $8.98M | 2.51% |
2021-06-30 | $8.76M | 20.82% |
2021-03-31 | $7.25M | -31.44% |
2020-12-31 | $10.57M | 17.89% |
2020-09-30 | $8.97M | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
IDEAYA Biosciences generated $7.00M in revenue during Q4 2024, up 100.00% compared to the previous quarter, and up 87.09% compared to the same period a year ago.
IDEAYA Biosciences Revenue Breakdown
IDEAYA Biosciences Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 22 | Dec 21 | Dec 20 |
---|---|---|---|
Methionine Adenosyl Transferase2 A Program Supply | $2.40M | $2.41M | $2.35M |
Methionine Adenosyl Transferase2 A Program Research And Development | - | $9.49M | $16.14M |
Polymerase Theta Program Research And Development Service | - | $13.75M | $25.78M |
The Option | - | $17.68M | $17.23M |
Werner Helicase Program Research And Development Service | - | $20.83M | $27.79M |
IDEAYA Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 22: Methionine Adenosyl Transferase2 A Program Supply (100.00%).
Quarterly Revenue by Product
Product/Service | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
---|---|---|---|---|---|---|---|---|---|
Werner Helicase Program Research And Development Service | $1.44M | $2.82M | $6.25M | $16.06M | $18.16M | $19.09M | $22.39M | $23.78M | $25.69M |
Polymerase Theta Program Research And Development Service | - | - | - | $2.12M | $10.00M | $11.27M | $12.76M | $17.32M | $22.39M |
Methionine Adenosyl Transferase 2 A Option Member | - | - | - | - | $17.47M | $17.49M | - | - | - |
Methionine Adenosyl Transferase2 A Program Research And Development | - | - | - | - | - | $3.78M | $10.29M | $13.02M | $14.77M |
The Option | - | - | - | - | - | - | $17.37M | $17.32M | $17.31M |
Methionine Adenosyl Transferase2 A Program Supply | - | - | - | - | - | - | $2.37M | $2.36M | $2.36M |
IDEAYA Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 23: Werner Helicase Program Research And Development Service (100.00%).
IDEAYA Biosciences Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
SWTX | SpringWorks Therapeutics | $191.59M | $61.55M |
DAWN | Day One Biopharmaceuticals | $131.16M | $29.21M |
ANAB | AnaptysBio | $91.28M | $43.11M |
AMLX | Amylyx Pharmaceuticals | $87.37M | $-665.00K |
VRNA | Verona Pharma | $42.28M | $76.26M |
MGTX | MeiraGTx | $33.28M | - |
SNDX | Syndax Pharmaceuticals | $23.68M | $20.04M |
RNA | Avidity Biosciences | $10.90M | $2.97M |
IDYA | IDEAYA Biosciences | $7.00M | $7.00M |
KROS | Keros Therapeutics | $3.55M | $3.04M |
XFOR | X4 Pharmaceuticals | $2.56M | $28.81M |
PTGX | Protagonist Therapeutics | - | $170.64M |
VTYX | Ventyx Biosciences | - | - |
RVMD | Revolution Medicines | - | - |
MLTX | MoonLake Immunotherapeutics | - | - |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
TERN | Terns Pharmaceuticals | - | - |